Rebecca S. Heist

TL;DR: Detailed genetic and histological analysis of 37 patients with drug-resistant non–small cell lung cancers carrying EGFR mutations provides new insights into the shifting sands of drug resistance evolution in lung cancers and suggests that serial biopsies may be essential in the quest to reverse or even prevent the development ofdrug resistance.

TL;DR: EML4-ALK defines a molecular subset of NSCLC with distinct clinical characteristics and patients who harbor this mutation do not benefit from EGFR TKIs and should be directed to trials of ALK-targeted agents.

TL;DR: Nivolumab monotherapy produced durable responses and encouraging survival rates in patients with heavily pretreated NSCLC, and overall survival, response durability, and long-term safety were reported.

TL;DR: Analysis of repeat biopsies from ALK-positive patients progressing on various ALK inhibitors finds that each ALK inhibitor is associated with a distinct spectrum of ALK resistance mutations and that the frequency of one mutation - ALK G1202R - increases significantly after treatment with second-generation agents.

TL;DR: Rociletinib was active in patients with EGFR-mutated NSCLC associated with the T790M resistance mutation and the only common dose-limiting adverse event was hyperglycemia.